Stockreport

Revolution Medicines: On Hold Pending A Lower Entry Point [Seeking Alpha]

Revolution Medicines, Inc.  (RVMD) 
PDF The company's RAS(ON) inhibitors will be tested in two registrational trials for pancreatic and lung cancer in the second half of 2024. Revolution Medicines has been [Read more]